 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2020, vol. 26, issue1
Subject Area: Medicine
-
DOI: 10.5272/jimab.2020261.2883
Published online: 22 January 2020
Original article
J of IMAB. 2020 Jan-Mar;26(1):2883-2886;
COMPLETE RESPONSE IN SYNCHRONOUS EARLY BREAST AND LUNG CANCER
Mariela Vasileva-Slaveva1
, Alexandrina Vlahova2, Spartak Valev3, Assia Konsoulova4, Svilen Masliankov1,
1) Department of Surgery, Alexandrovska University Hospital, Sofia, Bulgaria.
2) Department of Pathology, Alexandrovska University Hospital, Sofia, Bulgaria.
3) Department of medical oncology, MBAL Nadezhda, Sofia, Bulgaria.
4) Department of medical oncology, Complex Oncological center Burgas, Bulgaria.
ABSTRACT:
This is a rare case of multiple primary malignancies (MPM) both diagnosed in early stage, for which the patient received multidisciplinary complex treatment and achieved no evidence of disease state. We present a 67-year-old woman admitted in the Department of General surgery, Alexandrovska University Hospital, in April 2017 and diagnosed with invasive ductal carcinoma in the inner lower quadrant of the right breast. During the detailed staging process was found also 2 cm adenocarcinoma in the left lung. The patient underwent upper left lobectomy as a single treatment for lung cancer and received neoadjuvant chemotherapy with Docetaxel, Trastuzumab, and Pertuzumab for breast cancer. After the performed breast-conserving surgery, the final pathological report showed pathologic complete response (pCR). The current treatment modalities provide prolongation of patients’ life, which will increase the rate of MPM. Excellent prognosis still can be achieved when the right management of the patient is applied.
Keywords: multiple primary malignances, breast cancer, pathologic complete response,
- Download FULL TEXT /PDF 1616 KB/
Please cite this article as: Vasileva-Slaveva M, Vlahova A, Valev S, Konsoulova A, Masliankov S. Complete response in synchronous early breast and lung cancer. J of IMAB. 2020 Jan-Mar;26(1):2883-2886. DOI: 10.5272/jimab.2020261.2883
Correspondence to: Mariela Vasileva-Slaveva, Alexandrovska University Hospital, Department of surgery, Medical Faculty, Medical University Sofia; 1, St. Georgi Sofiiski blvd., 1431 Sofia, Bulgaria; E-mail: sscvasileva@gmail.com
REFERENCES:
1. Irimie A, Achimas-Cadariu P, Burz C, Puscas E. Multiple primary malignancies--epidemiological analysis at a single tertiary institution. J Gastrointestin Liver Dis. 2010 Mar;19(1):69-73. [PubMed]
2. Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017 May 2;2(2):e000172. [PubMed] [Crossref]
3. Howe HL (ed). A Review of the Definition for Multiple Primary Cancers in the United States. Workshop Proceedings From December 4–6, 2002, in Princeton, New Jersey. Springfield (IL): North American Association of Central Cancer Registries, May 2003. [Internet]
4. Valerianova Z, Atanasov T, Vukov M. (eds.) Cancer Incidence in Bulgaria, 2014 & 2015. Bulgarian National Cancer Registry. Sofia. 2017 vol.25. [Internet]
5. Li F, Zhong WZ, Niu FY, Zhao N, Yang JJ, Yan HH, et al. Multiple primary malignancies involving lung cancer. BMC Cancer. 2015 Oct 14;15:696. [PubMed] [Crossref]
6. Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol. 2015 Jan;114(1):56-65. [PubMed] [Crossref]
7. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32. [PubMed] [Crossref]
8. Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016 Jun;17(6):791-800. [PubMed] [Crossref]
9. Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, et al. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res. 2017 Feb 9;19(1):16. [PubMed] [Crossref]
10. Singh JC, Mamtani A, Barrio A, Morrow M, Sugarman S, Jones LW, et al. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. Oncologist. 2017 Feb;22(2):139-143. [PubMed] [Crossref]
11. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-72. [PubMed] [Crossref]
12. Krishnan Y, Al Awadi S, Sreedharan PS, Sujith Nair S, Thuruthel S. Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait. Asia Pac J Clin Oncol. 2016 Mar;12(1):e30-7. [PubMed] [Crossref]
13. Vasileva M, Masliankov S, Vlahova A, Genadieva M, Pavlov V, Zahariev Z, et al. [Pathologic response to preoperative systemic therapy in breast cancer patients- achievable prognostic factor.] [in Bulgarian] Book from the 16th National congress of Surgery, Bulgarian Surgical Society. 2018; 1:632-642. [Internet].
Received: 19 March 2019
Published online: 22 January 2020